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ABSTRACT 
 
The effects of mimosine (MI), which is an amino acid that is derived from Leucaena leucocephala, were evaluated 
on the growth of ascitic Ehrlich tumors, and the effects of the combination treatment of MI and cyclophosphamide 
(CY) on tumor growth were also assessed. Mice were divided into groups that received the following treatments 
over the course of 20 days: phosphate buffer solution (CO), MI, Ehrlich cells (E), E plus CY (EC), E plus MI (EM) 
and E plus MI and CY (EMC). No signs of toxicity were detected in the mice from the MI group. The mice from the 
EMC group showed reductions in body weights when compared with those from the E group. The animals from the 
EC, EM and EMC groups showed reductions in ascitic volume compared with those from the E group. The mice 
from the EMC group showed reductions in total cell numbers of ascitic fluid compared with those from the E, EC 
and EM groups. The combination of MI and CY was the most effective treatment for Ehrlich tumor ascites. 
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INTRODUCTION 
 
It is well known that many compounds with 
pharmacologic properties were first identified as 
poisonous substances; however, further 
investigations have revealed clinical therapeutic 
applications. In fact, botulinum toxins, which are 
exotoxins of Clostridium botulinum, are the most 
toxic naturally occurring substances known to 
man, but they also possess many clinical uses 
(Erbguth 2008). Many examples of poisonous 
plant-derived therapeutics have been reported in 
the literature, such as digoxin and digitoxin from 
Digitalis purpurea (Clark 1996), taxol from the 
Taxus species (Schiff and Horwitz 1980), 
pilocarpine from Pilocarpus jaborandi 
(Farnsworth et al. 1985) and many others. 
Therefore, the greatest challenge for 
phytochemical and pharmacological studies 
involves the identification of the specific 
compounds that are responsible for the beneficial 
effects and their modes of action, thereby 
delineating their useful functions as therapeutic 
drugs.  
Leucaena leucocephala is a species that originated 
in Central America and is now found in tropical 
regions around the world (Górniak 2008). This 
plant is highly nutritious, palatable and digestible 
for ruminants (Radostits et al. 2000). Additionally, 
it is a rich source of proteins, minerals and  
β-carotene (Akbar and Gupta 1985). However, 
many studies have shown that the use of leucaena 
forage has been limited due to its content of 
mimosine (MI) (β-[N-(3-hydroxyl-4(1H)-
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pyridone)], which is a non-protein amino acid that 
causes toxic effects in both ruminants and non-
ruminants (Radostits et al. 2000; Tokarnia et al. 
2000), including alopecia, cataracts, gum atrophy, 
tongue and esophageal ulcerations, goiter, 
infertility and reduced weight gain (Radostits et al. 
2000). It is known that cell mitotic activities in the 
epithelia of the esophagus, tongue, gums and 
intestines are high, and exposure to MI causes 
damage to these tissues (Hegarty et al. 1976). 
Many studies have been performed to better 
understand MI activity. Lalande and Hanauske-
Abel (1990) have shown that MI induces cell 
arrest (reversibly) late in the G1 phase of the cell 
cycle. Additionally, it is a tyrosine analog 
(Thompson et al. 1997) that contains a metal-
chelating domain.  More specifically, it is able to 
chelate transition metals, such as Fe3+ (Linn et al. 
1996), and the possible structure of the Fe (III)-MI 
chelation complex has been proposed by Tsai and 
Ling (1973). Furthermore, it has been 
demonstrated that MI inhibits various mammalian 
enzymes in vitro, such as tyrosinase, dopamine 
hydroxylase (Hashiguchi and Takahashi 1977), 
deoxyhypusyl hydroxylase (DOHH) (Abbruzzese 
et al. 1991), and H1 kinase (Feldman and 
Schonthal 1994). These results indicate that MI 
may inhibit the intense mitotic activity of cancer 
cells. In fact, in vitro studies have shown that MI 
represses uterine cancer cell growth (Zalatnai 
2005) and blocks DNA replication in both breast 
cancer and Chinese hamster ovary cells (Mosca et 
al. 1992).  
While many studies have been conducted to better 
understand the toxic effects of MI and its 
corresponding mechanism of action, information 
regarding its effects on tumor cells is lacking. 
Thus, the aim of this work was to evaluate the 
effects of MI on the growth of ascitic Ehrlich 
tumors in Swiss mice that received the MI 
treatment alone and in combination with a classic 
chemotherapeutic drug, cyclophosphamide (CY). 
 
 
MATERIALS AND METHODS 
 
Mice 
Sixty male Swiss mice (sixty-day-old) that were 
bred at the Department of Pathology at the School 
of Veterinary Medicine and Animal Sciences, 
University of São Paulo, were used for the 
experiments. The mice were maintained under 
controlled temperature (22–25°C), relative 
humidity (50–65%) and lighting (12 h light/12 h 
dark cycles) conditions. Both drinking water and a 
standard diet Nuvilab- CR1® from Nuvital 
Nutrientes LTDA (Curitiba, PR, Brazil) were 
provided ad libitum. All of the procedures were 
reviewed and approved by the Bioethics 
Committee of the FMVZ-USP (process number 
2452/2011). 
 
Chemicals 
MI was obtained from Sigma Chemical Co. (St. 
Louis, MO) and initially dissolved in Tris buffer at 
pH 8.9; the pH was subsequently adjusted to 7.2 
with 1 N HCl. Before administration, the MI 
solution was freshly diluted with physiologic 
saline to the required concentration. Both dopalen 
(ketamine) and anasedan (xylazine) were obtained 
from Vetbrands (São Paulo, SP, Brazil). Genuxal 
(cyclophosphamide) was obtained from Astra 
Medica Oncologia (São Paulo, SP, Brazil).  
 
Tumor Model 
Ehrlich ascites carcinoma (EAC) cells that were 
syngeneic to Swiss mice were used for the tumor 
model in this study. The EAC cells were 
transplanted intraperitoneally (IP) into the Swiss 
mice, and only the fluid transplant generations that 
were passed over 12 times resulted in the 
formation of regular exudates. Before 
transplantation, the cells were washed three times 
in phosphate buffer solution, and cell viability was 
assayed via trypan blue exclusion. The tumor cells 
(5x105 cells) were injected (IP) on the first day of 
the experiment. 
 
Treatment Protocol and Evaluations 
MI was administered at 30.0 mg/kg, and CY was 
administered at 12.5 mg/kg. Sixty Swiss mice 
were randomly divided into 6 groups (n=10) that  
received the following treatments by IP injection  
over the course of 20 days: phosphate-buffered 
saline (control group – CO), Ehrlich cells (E), 
Ehrlich cells plus MI (EM), Ehrlich cells plus CY 
(EC), Ehrlich cells plus MI and CY (EMC) and MI 
alone (MI). The animals from the MI group were 
used to insure that the MI dosage was not toxic. 
Ascitic volumes and tumor cellularities were not 
evaluated in the CO and MI groups because these 
animals did not receive tumor cells. One day after 
the last day of treatment, all of the animals were 
anesthetized with ketamine (100 mg/kg) and 
xylazine (10 mg/kg) and subjected to cervical 
dislocation, and the ascitic fluid was then collected 
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and centrifuged at 4000 rpm for 10 min. The 
supernatant was discarded, and the cells were 
resuspended in phosphate buffer solution (PBS). 
This solution was diluted in trypan blue, and the 
total live and dead cells were quantified using a 
Neubauer chamber. Body weight gain was 
measured on the first and last days of treatment. 
The incidence of alopecia was observed daily by 
visual inspection. 
 
Statistical Analysis 
The data were analyzed with GraphPad Prism 
5.00® software (GraphPad Software, Inc., San 
Diego, CA) using the one-way analysis of variance 
(ANOVA) followed by Tukey’s test for multiple 
comparisons. Data were expressed as the mean ± 
SD, and the differences were considered to be 
statistically significant at p<0.05. 
RESULTS 
 
The animals from the EMC group showed 
significant reductions (p<0.05) in body weight 
gain (Fig. 1A) compared with those from the E 
group. The same differences were detected when 
comparing the animals from the CO and MI 
groups. Additionally, the ascitic volumes that were 
observed in the mice from the EMC, EC and EM 
groups were lower than those from the E group 
(Fig. 1B); however, the EMC mice displayed 
smaller volumes compared with those from the 
EM and EC groups. The EMC mice also showed 
reductions in tumor cell numbers (Fig. 2A) 
compared with those from all of the other groups. 
Additionally, statistical analyses revealed that the 
live and dead tumor cells (Figs. 2B and 2C) were 
reduced exclusively in the mice from the EMC 
group compared with those from the E group. 
 
 
 
 
Figure 1 - The body weight (A) and ascitic volume (B) measurements that were obtained from the 
mice that received 20 days of treatment with CY and/or MI and no treatment. 
Phosphate-buffered saline (control group – CO), MI alone (MI), Ehrlich cells (E), 
Ehrlich cells plus CY (EC), Ehrlich cells plus MI (EM) and Ehrlich cells plus MI and 
CY (EMC). The letters indicate the statistical significances at p<0.05 as determined via 
Tukey’s test. 
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Figure 2 - The total cell (A), live cell (B), and dead cell numbers (C) of the ascitic Ehrlich tumors 
that were isolated from the mice that were either treated with CY and/or MI or 
untreated for 20 days. Ehrlich cells (E), Ehrlich cells plus CY (EC), Ehrlich cells plus 
MI (EM), and Ehrlich cells plus MI and CY (EMC). The letters indicate the statistical 
significances at p<0.05 as calculated via Tukey’s test. 
 
 
 
DISCUSSION 
 
The Ehrlich tumor, which is derived from a mouse 
adenocarcinoma, has been used as a transplantable 
tumor model to investigate the antineoplastic 
effects of many substances and compounds. 
Following the intraperitoneal inoculation of 
Ehrlich tumor cells, ascitic volumes increase 
progressively (Vincent and Nicholls 1967). This 
ascitis likely occurs due to tumor-induced 
inflammation resulting from the increased 
peritoneal vascular permeability (Fastaia and 
Dumont 1976). The impaired peritoneal lymphatic 
drainage by tumor cells (Fastaia and Dumont 
1976), the mechanic pressure that is exerted by the 
progressive increase in ascitic fluid, intraperitoneal 
hemorrhage and endotoxemia represent additional 
consequences of Ehrlich ascitic tumor 
development, which result in the death of the 
affected animals (Hartveit 1965; Mayer 1966).  
The aggressiveness of the Ehrlich tumor and its 
rapid growth make it a good model to investigate 
the possible synergistic effects of anticancer 
therapies using different mechanisms of action, as 
verified in a recent study that was conducted by 
Santos et al. (2011), in which treatment with a 
plant compound was analyzed in combination with 
the chemotherapeutic drug, cisplatin. In our study, 
this model also permitted the assessment of 
whether MI and CY cause any interactions and/or 
reduce tumor development.  
Many chemotherapeutic agents and drug 
combinations are very toxic to patients; for 
example, doxorubicin-associated cardiotoxicity 
(Mackay et al. 1994), the hepatotoxicity of 
cisplatin (Cavalli et al. 1978; Cersosimo 1993; 
Pollera et al. 1987) and the neurotoxicity of 
paclitaxel (Postma et al. 1995). In this study, we 
verified that MI-treated mice did not display any 
reductions in body weight or show any other 
clinical manifestations of MI-induced toxicity, 
such as hair loss (Crounse et al. 1962). Therefore, 
the dose that was applied in this study does not 
appear to be toxic; however, additional studies 
using accurate protocols of toxicological 
evaluation are necessary to confirm this 
hypothesis. While no differences in the tumor cells 
were detected between the mice from the Ehrlich 
cell (E) group and those from the isolated 
treatment (CY and MI) groups, consistent 
differences were observed when the animals were 
treated with the CY and MI combination 
treatment, which suggests that this combination is 
effective in restricting ascitic tumor development.   
CY is one of the most important alkylating drugs 
that is currently employed to treat cancer, and its 
mechanism of action involves the prevention of 
cell division primarily by the cross-linking of 
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DNA and RNA strands, which interrupts mitosis 
(Fleming 1997). In contrast, it has been proposed 
that MI acts as an iron chelator (Kulp and Vulliet 
1996), and it is known that iron deficiency alters 
folate metabolism in mammals and can interfere 
with tumor cell growth (Gilbert et al. 1998).  
Goldin and Mantel (1957) have proposed that the 
synergic mechanism of xenobiotics results in 
tumor damage because each agent acts on different 
cellular metabolic pathways. Thus, it is possible 
that synergism occurred when the amino acid was 
combined with the chemotherapeutic agent; 
moreover, MI and CY likely act in a synergistic 
fashion due to their varying antimetabolic 
properties. 
Additionally, MI inhibited Ehrlich tumor growth 
via its activity in the immune system. In fact, a 
study that was conducted by Frydas et al. (2003) 
has verified that in mice with experimentally 
induced subcutaneous granulomas that were 
treated with IP injections of MI, significantly 
decreased granuloma sizes and weights and the 
strong inhibition of TNF-α were displayed in both 
their sera and granulomas. Thus, future studies 
evaluating the immune systems of animals that 
have been treated with MI would assist in further 
verification. 
In conclusion, this work proposes a new 
combination treatment that inhibits tumor 
development. Our results reveal that MI enhances 
Ehrlich carcinoma cell sensitivity to CY as 
demonstrated by the improvement in the 
effectiveness of the antitumor treatment following 
combination therapy. However, further studies 
must be performed to verify the impacts of the 
toxic effects of MI during prolonged exposure. 
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